STENOCARE Change in the Board of Directors

Report this content

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER:  STENO

This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 01, 2024.

STENOCARE A/S (“Stenocare” or the “Company”) is changing the Board of Directors. Board member Søren Kjær will leave the board. The Company will nominate Rolf Steno to join the Board at the next general meeting.

The Company has accepted the resignation from Board member Søren Kjær and would like to thank him for his contribution to the Board of Directors.

The Company will nominate Rolf Steno to join the Board of Directors at the next general meeting. Rolf Steno has a background in sales and international business development.

For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO          Phone: +45 31770060            E-mail:
presse@stenocare.com

STENOCARE’s Certified Adviser is Keswick Global AG / Phone: +43 1 740 408045 / E-mail: info@keswickglobal.com

About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The Company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.   www.stenocare.com  www.stenocare.dk